SK bioscience Co.,Ltd. (KOSE: A302440)
Health Care · Biotechnology · KR
₩36,500.00
+2.10% today · -20.7% 1Y
SK bioscience Co.,Ltd. (KOSE: A302440) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.12B.
Over the last twelve months the share price has lost 20.7%, trading between 31.80K and 61.30K.
Tweenvest scores SK bioscience Co.,Ltd. across four factors: quality 79/100, value 66/100. Its strongest factor is quality.
A302440 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.12B
- Revenue (TTM)
- $425.71M
- P/E
- —
- EPS
- -1,080.96
- Dividend yield
- —
- Beta (5Y)
- 0.86
- 52-week high
- ₩61,300.00
- 52-week low
- ₩31,800.00
- Avg volume (3M)
- —
- Shares outstanding
- 78.04M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Anhui Anke Biotechnology (Group) Co., Ltd.SZSE: 300009 | $2.14B | CN¥8.61 | +3.49% |
| ABL Bio Inc.KOSDAQ: A298380 | $2.14B | ₩51,400.00 | +1.18% |
| Aurinia Pharmaceuticals Inc.NasdaqGM: AUPH | $2.13B | $16.12 | +0.69% |
| Wuhan Healthgen Biotechnology Corp.SHSE: 688765 | $2.12B | CN¥39.84 | -2.95% |
| Nanjing Vazyme Biotech Co., LtdSHSE: 688105 | $2.10B | CN¥27.24 | +2.52% |
| Mineralys Therapeutics, Inc.NasdaqGS: MLYS | $2.09B | $22.01 | -6.86% |
| Vericel CorporationNasdaqGM: VCEL | $2.06B | $40.12 | -0.07% |
| UroGen Pharma Ltd.NasdaqGM: URGN | $2.02B | $37.73 | -8.86% |
Figures last refreshed Oct 4, 2026.